$KRTX News
Last published 2y ago
- 2y agoAKLIBMYKRTXPRTC+1PureTech Announces Annual Results for Year Ended December 31, 2023Business WireSignificant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for Seaport, and the $14
- 2y agoKRTXKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateBusiness WireNew Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults under review with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024 Results from the Phase 3 EMERGENT-2 trial
- 2y agoBATLKAMNKRTXSNCEKuehn Law Encourages KAMN, SNCE, KRTX, and BATL Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoKRTXMGRCSNCEVINEKuehn Law Encourages SNCE, MGRC, VINE, and KRTX Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoMRKBMYJNJABBV+5Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugsCNBCFast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
- 2y agoAMAMAYXEGLEKRTXKuehn Law Encourages AYX, EGLE, AMAM, and KRTX Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoKRTXDSKERYZBGRCLKuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoKRTXBMYGSKaruna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion dealCNBCBristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.
- 2y agoBMYKRTXPRTCPureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 BillionBusiness WireTransaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy,
- 2y agoBMYKRTXBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna TherapeuticsBusiness WireTransaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy,
- 2y agoAKLIKRTXPRTCVORPureTech Year End Update and Outlook for 2024Business WireStrong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust balance sheet position
- 2y agoKRTXKaruna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in SchizophreniaBusiness WireKarXT demonstrated statistically significant and clinically meaningful improvements in positive and negative symptoms of schizophrenia compared to placebo, as measured by primary and secondary endpoints KarXT was
- 2y agoKRTXPRTCPureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaBusiness WirePrescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The application is
- 2y agoKRTXKaruna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaBusiness WirePrescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The application is
- 2y agoKRTXPRTCPureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaBusiness WireResults demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic
- 2y agoKRTXKaruna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaBusiness WireResults demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic
- 3y agoKRTXKaruna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call TranscriptEarnings Call Transcripts
- 3y agoKRTXKaruna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesBusiness WireSubmitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KarXT for the treatment of schizophrenia in the third quarter of 2023 Initiated the Phase 3 ADEPT-2 and ADEPT-3 trials evaluating
- 3y agoKRTXKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute CongressBusiness WireAnalyses of pooled efficacy data from the EMERGENT program demonstrate significant improvements in schizophrenia symptoms Analyses extend prior findings that KarXT is generally well tolerated with a low risk of common
- 3y agoKRTXKaruna Therapeutics to Present at Upcoming Investor ConferencesBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that
- 3y agoKRTXKaruna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023Business WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that
- 3y agoAKLIKRTXPRTCPureTech to Present at Two Upcoming Investor ConferencesBusiness WireCompany summarizes third quarter progress across its Wholly Owned Pipeline and Founded Entities PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage
- 3y agoKRTXKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) CongressBusiness WireNew efficacy, safety and tolerability analyses from the EMERGENT-3 trial support KarXT's potential as a new treatment option for schizophrenia Exploratory analysis will examine KarXT's impact on cognition in
- 3y agoKRTXPRTCKarXT, invented at PureTech, submitted for FDA Approval in SchizophreniaBusiness WireFounded Entity Karuna Therapeutics submits New Drug Application to U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia If approved, KarXT will be the first new mechanism in over 50 years for
- 3y agoKRTXKaruna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of SchizophreniaBusiness WireKarXT, a dual M1/M4 muscarinic agonist, represents the first new mechanism of action to treat schizophrenia in several decades, if approved Submission is supported by data from three positive registrational trials
- 3y agoKRTXKaruna Therapeutics to Present at Upcoming Investor ConferencesBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoAKLIKRTXPRTCVORPureTech Health plc – Half-Year ReportBusiness WireStrong progression of PureTech's Wholly Owned Pipeline, with three clinical-stage therapeutic candidates being evaluated across four clinical trials to address large patient needs in pulmonary, oncology and CNS
- 3y agoKRTXKaruna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoKRTXKaruna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesBusiness WireOn track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a product launch in the second half of 2024, assuming approval Initiated the Phase 3
- 3y agoKRTXKaruna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023Business WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXKaruna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual MeetingBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXKaruna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business UpdatesBusiness WireAnnounced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023 On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. FDA in
- 3y agoKRTXKaruna Therapeutics to Present at Upcoming Investor ConferencesBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoAKLIBIIBKRTXPRTC+1PureTech Announces Annual Results for Year Ended December 31, 2022Business WireStrong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million1 and consolidated cash, cash equivalents and short-term investments of $350.1 million,2 as of December 31,
- 3y agoKRTXKaruna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023Business WireConference call and webcast to take place on Thursday, May 4, 2023 at 8:00 a.m. ET Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative
- 3y agoKRTXKaruna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX) ("Karuna"), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today
- 3y agoKRTXKaruna Therapeutics to Present at the Stifel 2023 CNS DaysBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXKaruna Therapeutics Announces Pricing of Public Offering of Common StockBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXKaruna Therapeutics Announces Proposed Public Offering of Common StockBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXZLABZai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in SchizophreniaGlobeNewswireThird positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a
- 3y agoKRTXKaruna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in SchizophreniaBusiness WireThird positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a
- 3y agoKRTXKaruna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business UpdatesBusiness WireTopline data from Phase 3 EMERGENT-3 trial anticipated in the first quarter of 2023 On track to submit New Drug Application (NDA) for KarXT in schizophrenia to the U.S. Food & Drug Administration (FDA) in
- 3y agoKRTXKaruna Therapeutics to Present at the SVB Securities Global Biopharma ConferenceBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXKaruna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio's Investigational TRPC4/5 Product CandidatesBusiness WireKaruna to obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 Goldfinch Bio assignment estate to receive $15 million
- 3y agoKRTXKaruna Therapeutics Appoints William P. Kane as Chief Commercial OfficerBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXKaruna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness WireKaruna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
- 3y agoKRTXMoore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law FirmPR NewswireNEW YORK, Dec. 29, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ:KRTX) breached their
- 3y agoAKLIBIIBGLSKRTX+2PureTech Provides End of Year Report on Key ProgressBusiness WireRapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and
- 3y agoKRTXMoore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ:KRTX) breached